## Clinical Diagnosis: Antiphospholipid Syndrome (APS) with Acute Arterial Thrombosis **Key Point:** This patient has **antiphospholipid syndrome (APS)** manifesting as acute arterial thrombosis in the setting of SLE. The diagnosis is supported by positive lupus anticoagulant and anticardiolipin antibodies (≥2 positive criteria) in a patient with thrombosis. Note: This is APS with arterial thrombosis — not catastrophic APS (CAPS), which requires ≥3 organ systems involved within 1 week. ## Diagnostic Criteria Met | Finding | Significance | |---------|-------------| | Positive lupus anticoagulant + anticardiolipin | Satisfies ≥2 laboratory criteria for APS (Sapporo/Sydney criteria) | | Acute arterial thrombosis (femoral artery) | Clinical criterion for APS | | Prolonged aPTT with thrombosis | Paradoxical in vitro anticoagulant effect of antiphospholipid antibodies | | Thrombocytopenia (95,000/μL) | Common in SLE and APS | | No atherosclerotic plaque on Doppler | Confirms thrombotic (not atherosclerotic) etiology | **Clinical Pearl:** The **paradoxical prolongation of aPTT** in the presence of thrombosis is characteristic of antiphospholipid syndrome. The anticoagulant effect is **in vitro only**; in vivo, antiphospholipid antibodies promote thrombosis by activating endothelium, platelets, and the complement system. ## Why Option C (UFH → Warfarin, INR 3–4) Is Correct **High-Yield:** Per current guidelines (EULAR 2019, ACR, and standard Indian PG consensus), **arterial thrombosis in APS** requires higher-intensity anticoagulation with a **target INR of 3–4**, compared to venous thrombosis (INR 2–3). Rationale: 1. Arterial thrombosis in APS carries a significantly higher recurrence risk than venous thrombosis 2. Arterial events (stroke, limb ischemia) are more morbid — limb loss, permanent neurological deficit 3. Higher INR overcomes the prothrombotic milieu created by antiphospholipid antibodies 4. Immediate bridging with **intravenous unfractionated heparin (UFH)** is used acutely, followed by transition to warfarin for long-term secondary prevention **Mnemonic:** **AAAA** — **A**rterial thrombosis in **A**ntiphospholipid syndrome = **A**ggressive **A**nticoagulation (INR 3–4) ## Why Option B (INR 2–3) Is Incorrect - INR 2–3 is the target for **venous** thromboembolism (DVT/PE) in APS - For **arterial** thrombosis in APS, INR 2–3 is insufficient and associated with higher recurrence rates - This distinction is a classic NEET PG high-yield point ## Why Option D (Thrombolysis + Aspirin) Is Incorrect - Systemic thrombolysis with alteplase is **not first-line** for peripheral arterial thrombosis in APS - Thrombocytopenia (95,000/μL) increases hemorrhagic risk with thrombolytics - Aspirin monotherapy is inadequate for secondary prevention of arterial APS — anticoagulation is required - Thrombolysis is reserved for acute STEMI or massive PE, not peripheral arterial thrombosis ## Why Option A (Surgical Embolectomy) Is Incorrect - The limb, while ischemic, shows **no features of irreversible ischemia** (no gangrene, no fixed mottling, no muscle rigor) — it is still potentially viable - The underlying etiology is **in situ thrombosis** (APS-mediated), not embolism — embolectomy is not the primary intervention - Anticoagulation is the definitive treatment for APS-related thrombosis; surgery is reserved for non-viable limbs or failed anticoagulation - Surgical intervention without anticoagulation in APS risks re-thrombosis **Clinical Pearl (Harrison's Principles, 21st ed.):** In APS with arterial thrombosis, long-term anticoagulation with warfarin at INR 3–4 is recommended. Immediate anticoagulation with UFH is the bridge therapy of choice in the acute setting.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.